Nova Scotia Hlth Halifax

Halifax, Nova Scotia B3H1V7

2 studies enrolling now · 13 studies all time

What they study most

Cardiovascular Risk, Chronic Kidney Disease, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Inflammation, Non-alcoholic Steatohepatitis, Obesity, Overweight, Type 2 Diabetes

Studies at this site

• A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight — Recruiting now
• AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight — Recruiting now
• Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide — Running, not enrolling
• Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH) — Running, not enrolling
• Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide — Running, not enrolling
• ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation — Completed
• A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight — Running, not enrolling
• A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight — Completed
• A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP) — Completed
• A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes — Completed
• A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes — Completed
• A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes — Completed
• A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6) — Completed